Rna Splicing Defects In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RNA splicing is a fundamental post-transcriptional process in which introns are removed from pre-mRNA and exons are joined to produce mature mRNA. Defects in this process have emerged as a central pathogenic mechanism across multiple [neurodegenerative diseases[/diseases, including [amyotrophic lateral sclerosis (ALS)[/diseases/als, [Frontotemporal Dementia (FTD)[/diseases/ftd, [Spinal Muscular Atrophy (SMA)[/diseases/spinal-muscular-atrophy, and increasingly [Alzheimer's disease[/diseases/alzheimers. The RNA-binding proteins [TDP-43[/proteins/tdp-43, [FUS[/proteins/fus-protein, and [SMN[/proteins/smn serve as master regulators of splicing, and their dysfunction leads to widespread mis-splicing events that compromise neuronal survival and function. The discovery of cryptic exon inclusion as a hallmark of [TDP-43 Proteinopathy[/mechanisms/tdp-43-proteinopathy has opened new therapeutic avenues, including antisense oligonucleotide (ASO) strategies that are already in clinical development [1].
The spliceosome is a large ribonucleoprotein complex composed of five small nuclear ribonucleoproteins (snRNPs: U1, U2, U4, U5, U6) and over 200 associated proteins. It catalyzes the two-step transesterification reaction that removes introns from pre-mRNA. [neurons[/entities/neurons are particularly dependent on precise splicing regulation because they express an exceptionally diverse transcriptome — the brain has the highest proportion of alternatively spliced transcripts of any organ, with neuronal genes often containing many exons subject to complex splicing patterns (Raj & Bhatt, 2017) [2].
Several features render [neurons[/entities/neurons uniquely susceptible to splicing defects:
[TDP-43[/proteins/tdp-43 (TAR DNA-binding protein 43) is an essential RNA-binding protein that regulates multiple aspects of RNA metabolism, including splicing, transport, stability, and translation. Under pathological conditions in [ALS[/diseases/als and [FTD[/diseases/ftd, [TDP-43[/entities/tdp-43 is depleted from the nucleus and forms cytoplasmic aggregates — a process termed [TDP-43[/entities/tdp-43 proteinopathy. This nuclear loss-of-function has devastating consequences for splicing regulation (Buratti, 2024) [3].
A major splicing regulatory function of [TDP-43[/entities/tdp-43 is to repress the inclusion of cryptic exons — normally silent intronic sequences that are incorporated into mature mRNA only when [TDP-43[/entities/tdp-43 function is lost. Unlike conserved alternative exons, cryptic exons are typically non-conserved, often introduce premature stop codons, and lead to either truncated protein products or nonsense-mediated mRNA decay (Ling et al., 2015) [4].
One of the most functionally significant cryptic exon events occurs in STMN2 (stathmin-2), which encodes a protein essential for [microtubule dynamics] and axonal regeneration. When [TDP-43[/entities/tdp-43 is depleted from the nucleus, a cryptic exon in intron 1 of STMN2 is included, leading to premature polyadenylation and a truncated, non-functional STMN2 mRNA. This results in loss of full-length STMN2 protein, impairing axonal maintenance and repair (Klim et al., 2019) [5].
Processing of STMN2 pre-mRNA is more sensitive to [TDP-43[/entities/tdp-43 loss of function than most other targets, making it one of the earliest and most robust markers of [TDP-43[/entities/tdp-43 pathology. STMN2 cryptic exon inclusion has been detected in post-mortem tissue from patients with ALS, FTD, and [Alzheimer's Disease with TDP-43 pathology (LATE)[/diseases/late (Prudencio et al., 2024) [6].
UNC13A encodes a protein critical for [synaptic] vesicle release at the presynaptic terminal. TDP-43 represses a cryptic exon in intron 20 of UNC13A, and loss of TDP-43 function leads to inclusion of this cryptic exon and reduced UNC13A protein levels (Brown et al., 2022; Ma et al., 2022).
Remarkably, common genetic variants in UNC13A (rs12973192 and rs12608932) that are among the strongest risk factors for ALS and FTD act by increasing the efficiency of cryptic exon inclusion when TDP-43 function is compromised. These risk variants strengthen a cryptic splice site, making the UNC13A transcript particularly vulnerable to TDP-43 loss. This represents a compelling example of how genetic risk variants and protein pathology converge on a single molecular mechanism (Brown et al., 2022) [7].
Splice-switching ASOs that block UNC13A cryptic exon inclusion robustly rescue UNC13A protein levels and restore normal synaptic function in TDP-43-depleted [neurons[/entities/neurons (Bhatt et al., 2024) [8].
Recent work has identified KCNQ2 as another TDP-43 splicing target. TDP-43 depletion causes mis-splicing of KCNQ2, which encodes a voltage-gated potassium channel, leading to [neuronal hyperexcitability[/mechanisms/neuronal-hyperexcitability — a feature observed early in ALS pathogenesis (Bhinge et al., 2025) [9].
[FUS[/proteins/fus-protein (Fused in Sarcoma) is an RNA-binding protein involved in transcription, splicing, and [DNA damage repair[/mechanisms/dna-damage-repair. Like TDP-43, FUS mutations cause [ALS[/diseases/als and [FTD[/diseases/ftd, and FUS pathology involves nuclear depletion and cytoplasmic aggregation. FUS regulates splicing through direct binding to pre-mRNA introns, particularly near alternatively spliced exons (Lagier-Tourenne et al., 2012) [10].
FUS depletion affects the splicing of hundreds of neuronal transcripts, with a preference for long introns in genes essential for neuronal function. Key affected targets include genes involved in:
FUS also interacts with [stress granules[/mechanisms/stress-granules, and disease-associated mutations enhance FUS recruitment to stress granules, sequestering it away from its nuclear splicing functions (Dormann et al., 2010) [11].
The survival motor neuron (SMN) protein, encoded by SMN1, is essential for the assembly of snRNPs — the core components of the spliceosome. Homozygous deletion or mutation of SMN1 causes [Spinal Muscular Atrophy (SMA)[/diseases/spinal-muscular-atrophy, the leading genetic cause of infant mortality. A paralogous gene, SMN2, produces predominantly a truncated, unstable SMN protein due to a C-to-T transition in exon 7 that promotes exon skipping (Lefebvre et al., 1995) [12].
The therapeutic correction of SMN2 splicing represents one of the greatest successes of splicing-targeted medicine:
These therapies demonstrate that splicing correction is a viable therapeutic strategy for neurodegenerative disease, providing a paradigm for similar approaches in ALS and FTD [13].
Recent research has revealed that SMN deficiency and depletion of splicing factors disrupt the nuclear localization of CHMP7, a component of the ESCRT-III complex. This leads to nuclear pore complex (NPC) injury — connecting splicing defects to [nucleocytoplasmic transport defects[/mechanisms/nucleocytoplasmic-transport-defects, another major mechanism in neurodegeneration (Bhatt et al., 2024) [14].
RNA splicing defects are part of a larger landscape of [RNA metabolism[/mechanisms/rna-metabolism dysregulation in neurodegeneration. Related mechanisms include:
Under cellular stress, RNA-binding proteins including TDP-43, FUS, and other splicing factors are recruited to cytoplasmic stress granules. In disease states, these stress granules may mature into pathological aggregates through [liquid-liquid phase separation[/mechanisms/liquid-liquid-phase-separation, permanently sequestering splicing factors away from the nucleus and creating a self-reinforcing cycle of splicing dysfunction (Wolozin & Ivanov, 2019) [15].
TDP-43 pathology occurs in approximately 25-50% of [Alzheimer's disease[/diseases/alzheimers cases, particularly in the [LATE[/diseases/late subtype. Cryptic exon inclusion in STMN2 and UNC13A has been detected in AD brain tissue, correlating with TDP-43 pathology burden but not with [amyloid-beta[/entities/amyloid-beta or tau] deposits (Prudencio et al., 2024). This suggests that splicing defects represent an independent pathogenic axis in AD [1].
[Huntington's disease[/mechanisms/huntington-pathway exhibits widespread splicing changes, particularly affecting genes involved in synaptic function and neuronal identity. The mutant [huntingtin[/proteins/huntingtin protein interacts with several splicing factors, sequestering them and altering their function [2].
Emerging evidence suggests that [prion-like spreading[/mechanisms/prion-like-spreading of TDP-43 and FUS aggregates may propagate splicing dysfunction across connected brain regions, providing a mechanism for the progressive nature of neurodegenerative diseases [3].
[ASOs[/technologies/antisense-oligonucleotides represent the most advanced therapeutic approach for correcting splicing defects:
| Target | Disease | Mechanism | Status |
|---|---|---|---|
| SMN2 exon 7 | SMA | Promote exon inclusion | FDA-approved (Nusinersen) |
| STMN2 cryptic exon | ALS/FTD | Block cryptic exon inclusion | Clinical development |
| UNC13A cryptic exon | ALS/FTD | Block cryptic exon inclusion | Preclinical |
| [HTT[/genes/htt exon 1 | HD | Reduce [huntingtin[/proteins/huntingtin expression | Clinical trials |
Small molecules that modulate splicing are an emerging therapeutic class:
[Gene therapy[/treatments/gene-therapy approaches including AAV-mediated delivery of functional RNA-binding proteins or replacement of affected genes are in preclinical development for multiple splicing-related neurodegenerative diseases [4].
Key areas of active investigation include:
The study of Rna Splicing Defects In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 0 references |
| Replication | 100% |
| Effect Sizes | 50% |
| Contradicting Evidence | 100% |
| Mechanistic Completeness | 50% |
Overall Confidence: 53%